{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T12:32:47Z","timestamp":1795264367042,"version":"4.10.3"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,9,21]],"date-time":"2007-09-21T00:00:00Z","timestamp":1190332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:title><jats:sc>Summary<\/jats:sc><\/jats:title><jats:p> <jats:bold>\n            <jats:styled-content>Purpose:<\/jats:styled-content> This multicenter, double\u2010blind, double\u2010dummy, randomized, inpatient trial evaluated the safety, tolerability, and pharmacokinetics of intravenous lacosamide as replacement for oral lacosamide in patients with partial\u2010onset seizures.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>\n            <jats:styled-content>Methods:<\/jats:styled-content> Patients were enrolled from an ongoing open\u2010label extension trial of oral lacosamide and randomized (2:1) to either intravenous lacosamide and oral placebo or intravenous placebo and oral lacosamide. During the 2\u2010day inpatient treatment period, patients received twice\u2010daily doses of lacosamide equivalent to their current daily dose of oral lacosamide. The first 30 patients enrolled received infusions with 60\u2010min durations and the next 30 received infusions with 30\u2010min durations.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>\n            <jats:styled-content>Results:<\/jats:styled-content> Of 60 patients randomized, 59 completed the trial. Treatment\u2010emergent adverse events (AEs) were reported by 16 patients and included dizziness, headache, back pain, somnolence, and injection site pain. The tolerability profile of intravenous lacosamide was consistent with that of oral lacosamide. All AEs were considered mild or moderate in intensity, and no serious AEs or AEs leading to withdrawal were reported.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>\n            <jats:styled-content>Conclusions:<\/jats:styled-content> Intravenous lacosamide, administered as 60\u2010 or 30\u2010min twice\u2010daily infusions, showed a similar safety and tolerability profile to oral lacosamide when used as replacement therapy. Results from this trial support further investigation of intravenous lacosamide at shorter infusion durations.<\/jats:bold> <\/jats:p>","DOI":"10.1111\/j.1528-1167.2007.01317.x","type":"journal-article","created":{"date-parts":[[2007,9,22]],"date-time":"2007-09-22T08:43:38Z","timestamp":1190450618000},"page":"418-424","source":"Crossref","is-referenced-by-count":95,"title":["Intravenous lacosamide as replacement for oral lacosamide in patients with partial\u2010onset seizures"],"prefix":"10.1111","volume":"49","author":[{"given":"Victor","family":"Biton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Whitesides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan B.","family":"Fountain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerija","family":"Vaiciene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. David","family":"Rudd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,9,21]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01188.x"},{"issue":"1","key":"e_1_2_6_3_1","first-page":"A187","article-title":"Efficacy and safety of adjunctive oral lacosamide for the treatment of partial\u2010onset seizures in patients with epilepsy","volume":"646","author":"Ben\u2010Menachem E","year":"2005","journal-title":"Neurology"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(00)00171-6"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(02)00106-7"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2004.07.010"},{"issue":"1","key":"e_1_2_6_7_1","first-page":"A119","article-title":"Safety, tolerability, and pharmacokinetics of intravenous lacosamide as replacement for oral lacosamide in subjects with partial seizures","volume":"646","author":"Biton V","year":"2005","journal-title":"Neurology"},{"issue":"7","key":"e_1_2_6_8_1","first-page":"307","article-title":"Food does not affect the pharmacokinetics of SPM 927","volume":"45","author":"Cawello W","year":"2004","journal-title":"Epilepsia"},{"issue":"7","key":"e_1_2_6_9_1","first-page":"188","article-title":"Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927","volume":"43","author":"Horstmann R","year":"2002","journal-title":"Epilepsia"},{"key":"e_1_2_6_10_1","first-page":"479","article-title":"SPM\u2010927 (Schwarz Pharma)","volume":"6","author":"Hovinga CA.","year":"2003","journal-title":"IDrugs"},{"issue":"8","key":"e_1_2_6_11_1","first-page":"170","article-title":"Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures","volume":"46","author":"Jatuzis D","year":"2005","journal-title":"Epilepsia"},{"issue":"7","key":"e_1_2_6_12_1","first-page":"123","article-title":"Bioequivalence of short\u2010time infusions compared to oral administration of lacosamide","volume":"45","author":"Kropeit D","year":"2004","journal-title":"Epilepsia"},{"key":"e_1_2_6_13_1","unstructured":"KropeitD ScharfeneckerU SchiltmeyerB KochB RuddGD CawelloW HorstmannR.(2005)Lacosamide has low potential for drug\u2010drug interaction.59th Annual Meeting of the American Epilepsy Society."},{"issue":"1","key":"e_1_2_6_14_1","first-page":"A433","article-title":"An open\u2010label, maximum tolerated dose trial to evaluate oral SPM 927 as adjunctive therapy in patients with partial seizures","volume":"60","author":"Sachdeo R","year":"2003","journal-title":"Neurology"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.1.1.49"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2007.01317.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2007.01317.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T06:07:48Z","timestamp":1695967668000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2007.01317.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,21]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1111\/j.1528-1167.2007.01317.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2007.01317.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,21]]}}}